Drug Shortage Report for TEVA-LENOLTEC NO. 1
Report ID | 132254 |
Drug Identification Number | 00653233 |
Brand name | TEVA-LENOLTEC NO. 1 |
Common or Proper name | LENOLTEC NO.1 CAPLET |
Company Name | TEVA CANADA LIMITED |
Market Status | MARKETED |
Active Ingredient(s) | ACETAMINOPHEN CAFFEINE CODEINE PHOSPHATE |
Strength(s) | 300MG 15MG 8MG |
Dosage form(s) | TABLET |
Route of administration | ORAL ORAL |
Packaging size | 200 |
ATC code | N02AJ |
ATC description | OPIOIDS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2021-01-20 |
Estimated end date | 2021-02-28 |
Actual end date | 2021-02-24 |
Shortage status | Resolved |
Updated date | 2021-02-25 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v1 | 2021-01-22 | English | Compare |
v2 | 2021-01-22 | French | Compare |
v3 | 2021-02-25 | English | Compare |
v4 | 2021-02-25 | French | Compare |
Showing 1 to 4 of 4